Kyowa Kirin Stock Plunges Over 10% on U.S. Drug Pricing Concerns

Shares of Kyowa Kirin (TYO:4151) plummeted in Tuesday's trading session, erasing the previous day's gains as investors reassessed the financial implications of a drug pricing agreement with the U.S. government.

A Sharp Reversal

The Japanese drugmaker's stock ended the session down 11.1% at ¥2,390, making it the worst performer on the Nikkei 225 index. The sell-off represented a stark reversal of sentiment from the prior day, when the stock had rallied on initial news of the pricing deal. The stock gapped down at the open and traded sharply lower throughout the day.

U.S. Pricing Deal Fuels Sell-Off

The initial optimism surrounding an agreement to lower drug prices for the U.S. Medicaid program quickly gave way to concern. According to Investing.com, the market is now focusing on the potential for mandated discounts to negatively impact Kyowa Kirin's revenue.

Ad

Investors are reportedly worried that the pricing arrangement is expanding to include a wider range of companies and products. This could translate into material losses for Kyowa Kirin’s North American business, which the company has identified as a key engine for growth.

Market Headwinds and Analyst Caution

The sell-off was compounded by a lack of institutional support and a weak broader market. A majority of sell-side analysts covering Kyowa Kirin hold Sell or Underweight ratings, with consensus price targets below recent trading levels.

Furthermore, a broader decline in Asian equities added a macro headwind. The benchmark Nikkei 225 index, of which Kyowa Kirin is a component, slid 2.7% during the session, providing no relief for the stock.